Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19253721 | 1.00 | HCRTR1 (0.33) | HCRTR1HCRTR2POLBMEN1MAPT | |
| SCHEMBL12713766 | 0.65 | KDM4E (0.40) | POLBMEN1MAPTKMT2A | |
| SCHEMBL19253755 | 0.65 | CTSL (0.37) | POLB | |
| SCHEMBL9226195 | 0.63 | PRKDC (0.34) | MAPT | |
| SCHEMBL25932310 | 0.63 | LATS1 (0.41) | POLBMEN1MAPTALOX15ALOX12 | |
| SCHEMBL16125184 | 0.61 | KRAS (0.44) | POLBMAPTKMT2A | |
| SCHEMBL11455279 | 0.61 | PKM (0.33) | POLBMEN1MAPTALOX15ALOX12 | |
| SCHEMBL28284997 | 0.61 | — | — | |
| SCHEMBL13356700 | 0.60 | PKM (0.38) | POLBMEN1MAPTALOX15ALOX12 | |
| SCHEMBL25931960 | 0.60 | ALDH1A1 (0.43) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209296-B1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240567-A1 | ETHYL N-BOC PIPERIDINYL PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | HCRTR1 3407/4885HCRTR2 4052/4885POLB 2279/4885 |
| US-10072025-B2 | Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors | JAK1, JAK2, JAK3 | HCRTR1 3407/4885HCRTR2 4052/4885POLB 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.